Crestor DTC Ads To Resume Following Safety Labeling Update
Executive Summary
AstraZeneca will resume direct-to-consumer ads for Crestor following the completion of labeling revisions that emphasize an increased risk of rhabdomyolysis, especially at the statin's highest approved dose
You may also be interested in...
To Crestor’s Foe, FDA Says Toxicity Is Low, But DTC Ads Must Go
FDA says AstraZeneca's Crestor is as safe as, if not safer than, other statins for a given LDL-lowering efficacy, but its ad campaign cannot claim superiority to Pfizer's Lipitor
To Crestor’s Foe, FDA Says Toxicity Is Low, But DTC Ads Must Go
FDA says AstraZeneca's Crestor is as safe as, if not safer than, other statins for a given LDL-lowering efficacy, but its ad campaign cannot claim superiority to Pfizer's Lipitor
Crestor Muscle Risk No Greater Than Other Statins, FDA Says; Death Reported
FDA's current view is that there is no greater risk for muscle injury with AstraZeneca's cholesterol lowering drug Crestor than with other statins, the agency said